<DOC>
	<DOCNO>NCT00746720</DOCNO>
	<brief_summary>The purpose study test hypothesis orally administer etoricoxib ( COX-2 ) modulate prostaglandin cytokine synthesis central nervous system ( CNS ) periphery surgical patient thus reduces pain suffering .</brief_summary>
	<brief_title>Modulation Surgical Inflammatory Response Etoricoxib</brief_title>
	<detailed_description>This study multiple centre , double-blind , placebo-controlled , randomize , parallel group study conduct male female adult patient undergo elective primary single hip arthroplasty . In part 1 study 12 patient enrol study administrate 120 mg Etoricoxib placebo orally day one post surgery . The result part 1 help adjust sample time point ( blood , cerebrospinal fluid hip drain fluid ) necessary . In part 2 study 40 patient enrol receive 120 mg etoricoxib placebo two hour 24 hour surgery . Primary end point inflammatory mediator peripheral central level . After surgical manipulation expect increase mediator side . It investigated medication could reduce mediator compare placebo effect relate pharmacokinetic parameter .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>Subject undergo elective primary single hip arthroplasty Subject diagnose Osteoarthritis / arthrosis Subject take nonsteroidal antiinflammatory drug within 4 terminal half life time prior enrollment Subject capable understanding cooperating requirement study Patients renal insufficiency ( serum creatinine &gt; 1.5 mg/dl ) Recent major trauma systemic infection ( within 3 month ) Use corticosteroid medication chronic opioids ( within 3 month ) Any condition likely affect prostaglandin cytokine level Participation another clinical study receipt investigational drug within 30 day Hypersensitivity component etoricoxib and/or placebo tablet Uncontrolled hypertension define systolic blood pressure &gt; 140 mm Hg diastolic pressure &gt; 90 mm Hg rest two repeat measurement Congestive heart failure ( NYHA IIIV ) Cerebrovascular disease Established ischemic heart disease ( include patient recently undergone coronary artery bypass graft surgery angioplasty ) Patients kind severity cirrhosis liver cholestasis elevate liver function enzyme ( ALT AST 3 fold ) sign clinical significant liver malfunction ( correspond ChildPughScore â‰¥5 ) Patients develop sign asthma , acute rhinitis , nasal polyp , angioneurotic oedema urticaria follow administration aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) Pregnancy lactation Patients active peptic ulceration active gastrointestinal ( GI ) bleed Inflammatory bowel disease Recent history ( within last year ) alcohol substance abuse An employee sponsor study site Any neurological syndrome condition lead contraindication spinal anesthesia</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>hip replacement</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>etoricoxib</keyword>
	<keyword>pain</keyword>
	<keyword>cerebrospinal fluid</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>